| Drug ID: | Drug141 |
|---|---|
| Drug Name: | Ascorbic acid |
| CID: | 54670067 |
| DrugBank ID: | DB00126 |
| Modality: | Small Molecule |
| Groups: | approved|nutraceutical |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT04457934, , NCT05726097, , NCT01929668, , NCT03581149 |
| Molecular Formula: | C6H8O6 |
| Molecular Weight: | 176.12 g/mol |
| Isomeric SMILES: | C([C@@H]([C@@H]1C(=C(C(=O)O1)O)O)O)O |
| Synonyms: | l-ascorbic acid; ascorbic acid; vitamin C; Ascoltin; Ascorbicap; Cevitamic acid; Laroscorbine; Testascorbic; Allercorb; Ascorbajen |
| Phase 0: | 17 |
| Phase 1: | 72 |
| Phase 2: | 151 |
| Phase 3: | 85 |
| Phase 4: | 81 |
| Description: | A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant. [PubChem] |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt1121 | 54670067 | Ascorbic Acid | 4780 | NFE2L2 | Homo sapiens (human) | None | |
| dt1122 | 54670067 | Ascorbic Acid | 9962 | SLC23A2 | Homo sapiens (human) | None | |
| dt1123 | 54670067 | Ascorbic Acid | 5351 | PLOD1 | Homo sapiens (human) | None | |
| dt1124 | 54670067 | Ascorbic Acid | 5617 | PRL | Homo sapiens (human) | None | |
| dt1125 | 54670067 | Ascorbic Acid | 2670 | GFAP | Homo sapiens (human) | None | |
| dt1126 | 54670067 | Ascorbic Acid | 1634 | DCN | Homo sapiens (human) | None | |
| dt1127 | 54670067 | Ascorbic Acid | 1588 | CYP19A1 | Homo sapiens (human) | None | |
| dt1128 | 54670067 | Ascorbic Acid | 572 | BAD | Homo sapiens (human) | 29992683 | [juglone co-treated with ascorbic acid] results in increased expression of BAD protein |
| dt1129 | 54670067 | Ascorbic Acid | 208 | AKT2 | Homo sapiens (human) | 30597948 | Ascorbic acid affects the expression of AKT2 mRNA |
| dt1130 | 54670067 | Ascorbic Acid | 59 | ACTA2 | Homo sapiens (human) | 17053324 | [mercaptoethanol co-treated with ascorbic acid] results in increased expression of ACTA2 protein |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT01929668 | Comparison of 4L Polyethylene Glycol and 2L Polyethylene Glycol With Ascorbic Acid in Inactive UC Patients | None | COMPLETED | Kyungpook National University Hospital | Ulcerative Colitis | DRUG: polyethylene glycol|DRUG: Ascorbic Acid | Details |
| NCT03581149 | Tolerability and Efficacy of Sodium Picosulfate/Magnesium Citrate Versus PEG/Ascorbic Acid in Ulcerative Colitis Patients | PHASE4 | UNKNOWN | American University of Beirut Medical Center | Ulcerative Colitis | DRUG: Sodium Picosulfate/Magnesium Citrate Laxati… | Details |
| NCT05726097 | Bowel Preparation Regimen for Colon Capsule Endoscopy Procedure | PHASE3 | COMPLETED | Region Skane | Colon Cancer; Inflammatory Bowel Diseases; Gastro… | DRUG: polyethylene glycol; DRUG: sodium phosphate… | Details |
| EUCTR2018-001402-28-ES | PROTOCOL FOR THE OPTIMIZATION OF THE PREPARATION FOR THE COLONOSCOPY IN PATIENTS WITH INTESTINAL INFLAMMATORY DISEASE | PHASE4 | Authorised | Hospital Universitario La Paz | preparation in patients with inflammatory bowel d… | Trade Name: Moviprep Sabor Naranja … | Details |
| ISRCTN69447524 | The effect of combined n-3 polyunsaturated fatty acid and antioxidant dietary supplements on Crohn's disease & the associated osteoporosis, malnutrition and morbidity | Not Available | Not Recruiting | NHS R&D Regional Programme Register - Department of Health (UK) | Digestive system diseases: Inflammatory bowel dis… | 1. The dietary intervention consists of: 9 capsul… | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| 1.0 | Crohn's disease | An intestinal disease that involves inflammation located_in intestine. | disease of anatomical entity gastrointestinal system disease, intestinal disease, inflammatory bowel disease | Obiltoxaximab; Budesonide; Hydrocortisone acetate; Sulfasalazine; Ursodeoxycholic acid; Pegunigalsidase alfa; Imiglucerase; Bictegravir; Taliglucerase alfa; Etelcalcetide; Cimetidine; Desonide | Crohn's disease is a relapsing systemic inflammatory diseas… | Details |
| 2.0 | ulcerative colitis | A colitis that is predominantly confined to the mucosa located_in colon and includes characteristic ulcers, or open sores. | disease of anatomical entity, gastrointestinal system disease, autoimmune disease of gastrointestinal tract; intestinal disease, inflammatory bowel disease, colitis; disease, primary immunodeficiency disease, autoimmune disease, autoimmune disease of gastrointestinal tract | Mirikizumab; Olsalazine; Balsalazide; Sulfasalazine; Budesonide; Hydrocortisone acetate; Tixocortol; Kappadione; Teicoplanin; Atezolizumab; Gamolenic acid; Upadacitinib | No abstract available | Details |
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S01 | Anti-inflammatory | inflammatory | 5-Aminosalicylates (5-ASAs); corticosteroids | Crohn's disease and ulcerative colitis are the two main com… | Details |
| S02 | Immunosuppression | Classic immunosuppressive drugs | azathioprine; 6-mercaptopurine; methotrexate; ciclosporin-A; tacrolimus | Ciclosporin-A and tacrolimus bind to specific intracellular… | Details |
| S03 | Anti-TNF agents | Tumor necrosis factor | infliximab; adalimumab; golimumab; certolizumab pegol | TNF is produced by various immune and non-immune cells in t… | Details |
| S04 | T-cell homing and retention | T-cell trafficking | vedolizumab; anti-MAdCAM1 antibodies ; etrolizumab | Inhibition of the interaction between α4β7 integrins on T c… | Details |
| S07 | Blockade of cytokine | Cytokine signalling | apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab | Various T-cell subsets, their differentiation pathways and … | Details |
| S08 | Strengthening barrier function | Modulation of barrier function | phosphatidylcholine (lecithin); imiquimod; mongersen | Escherichia coli Nissle (EcN) is a nonpathogenic Gram-negat… | Details |
| S09 | Stem cells Transplantation | mesenchymal stem cells (MSCs) | MSC | Crohn's disease is associated with the development of compl… | Details |
| S11 | Improveming Intestinal Microecology | the intestinal microbiota | antibiotics; probiotics; prebiotics; postbiotics; synbiotics; fecal microbiota transplantation (FMT) | The imbalance between beneficial bacteria and harmful patho… | Details |
Perspectives About Ascorbic Acid to Treat Inflammatory Bowel Diseases
PMID: 38467159
Year: 2024
Relationship Type:
Mechanism
Score: 8.5
It is known that reactive oxygen species cause abnormal immune responses in the gut during inflammatory bowel diseases (IBD). Therefore, oxidative st…
Ascorbic acid ameliorates oxidative stress and inflammation in dextran sulfate …
PMID: 26884937
Year: 2015
Relationship Type:
Treatment
Score: 7.3
Ascorbic acid (AA) has been shown to exert beneficial effects, including mitigating oxidative stress and inhibiting inflammation. However, the preven…
Treatment of ulcerative colitis by sustained release curcumin pellets coated wi…
PMID: 40228426
Year: 2025
Relationship Type:
Treatment
Score: 6.5
The present work aimed to protect the rapid reduction of Curcumin (Cur) in alkaline pH by newly synthesized ethyl ascorbic acid (EAA) in dual-coated …
Cortisone-loaded stearoyl ascorbic acid based nanostructured lipid carriers all…
PMID: 36958119
Year: 2023
Relationship Type:
Treatment
Score: 6.5
Ulcerative colitis is a chronic inflammatory disease which poorly affects the colon and spreads toward the rectum over time. Cortisone (CRT) is a cor…
Oral Sulfate Solution Is as Effective as Polyethylene Glycol with Ascorbic Acid…
PMID: 36588527
Year: 2023
Relationship Type:
Treatment
Score: 6.5
BACKGROUND/AIMS: Low-volume preparations for colonoscopy are gaining attention for their higher acceptability. However, the efficacy and safety of or…
2-O-β-d-Glucopyranosyl-l-ascorbic Acid, an Ascorbic Acid Derivative Isolated fr…
PMID: 31556290
Year: 2019
Relationship Type:
Mechanism
Score: 6.5
Previous studies have shown that inhibition of receptor-interacting serine/threonine kinase (RICK) (also known as RIP2) results in amelioration of …
Comparison of 4-L Polyethylene Glycol and 2-L Polyethylene Glycol Plus Ascorbic…
PMID: 28639128
Year: 2017
Relationship Type:
Adverse Effect
Score: 6.3
BACKGROUND: Although colonoscopy preparation may cause symptom flares in patients with ulcerative colitis (UC), little is known about the standard pr…
High-dose vitamin C therapy for symptomatic deficiency in a patient with myasth…
PMID: 34784069
Year: 2022
Relationship Type:
Treatment
Score: 5.5
Vitamin C (ascorbic acid) is an essential water-soluble antioxidant, and deficiency (ie, plasma level <11 mumol/L) can result in scurvy. People at th…
Vitamin C Deficiency and the Risk of Osteoporosis in Patients with an Inflammat…
PMID: 32751086
Year: 2020
Relationship Type:
Association
Score: 5.5
Recent research studies have shown that vitamin C (ascorbic acid) may affect bone mineral density and that a deficiency of ascorbic acid leads to the…